Zacks Investment Research downgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to Hold in a report released today.
- Updated: October 8, 2016
Yesterday Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded 1.71% higher at $11.70. The company’s 50-day moving average is $11.93 and its 200-day moving average is $10.95. The last stock close price is up 5.87% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 325,802 shares of the stock were exchanged, down from an average trading volume of 529,502
Zacks Investment Research has downgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to Hold in a report released on Wednesday October 05, 2016.
Previously on 10/04/2016, Zacks Investment Research reported about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) raised the target price from $0.00 to $13.00. At the time, this indicated a possible upside of 0.11%.
See Chart Below
Momenta Pharmaceuticals, Inc. has a 52 week low of $7.86 and a 52 week high of $18.85 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 9 firms have reported on the stock. The consensus target price is $16.33 with 5 firms rating the stock a strong buy, 1 firm rating the stock a buy, 3 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.